Infections caused by drug-resistant pathogens are on the rise. Daptomycin, a cyclic lipopeptide with activity against most Gram-positive pathogens, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus, is a newly US-FDA approved antimicrobial for complicated skin and skin structure infections (cSSSI). Daptomycin has a unique mechanism of action that results in destruction of the membrane potential. The rapid bactericidal activity of daptomycin makes it an attractive antibiotic for serious Gram-positive infections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dkh546 | DOI Listing |
Publication Analysis
Top Keywords
serious gram-positive
8
gram-positive infections
8
daptomycin
4
daptomycin lipopeptide
4
lipopeptide antibiotic
4
antibiotic treatment
4
treatment serious
4
infections
4
infections infections
4
infections caused
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!